EGFR突变腺癌转化为小细胞肺癌及其他高级别神经内分泌癌:临床结局
该多中心回顾性研究纳入67例EGFR突变小细胞肺癌及其他高级别神经内分泌癌患者,从中位转化时间17.8个月、转化后中位生存10.9个月,铂类-依托泊苷和紫杉类反应率高,但17例接受免疫治疗者无一例反应。
要点
- EGFR突变非小细胞肺癌可转化为小细胞肺癌,中位转化时间17.8个月(95%CI 14.3-26.2)。
- 转化后铂类-依托泊苷和紫杉类反应率高,但17例接受免疫治疗者均无反应。
- 转化后常伴Rb1、TP53和PIK3CA突变,中枢神经系统转移常见。
核心结论
- EGFR突变非小细胞肺癌可发生小细胞肺癌转化,转化后对铂类-依托泊苷和紫杉类反应常见,但检查点抑制剂无反应,需进一步研究以阐明该人群的最佳策略。
研究设计与样本
- 多中心回顾性研究,纳入8家机构收治的67例EGFR突变小细胞肺癌及其他高级别神经内分泌癌患者(38例女性,29例男性)。
主要发现
- 初诊肺癌时58例为非小细胞肺癌,9例为原发小细胞肺癌或混合组织学;除这9例外,其余患者均在转化前接受过一种或多种EGFR酪氨酸激酶抑制剂。
- 中位转化时间为17.8个月(95%CI 14.3-26.2个月)。
- 自诊断起中位总生存为31.5个月(95%CI 24.8-41.3个月),自小细胞肺癌转化起中位生存为10.9个月(95%CI 8.0-13.7个月)。
- 59例在首次发现小细胞肺癌时进行组织基因分型,均保留创始EGFR突变;19例既往EGFR T790M阳性者中15例在转化时为T790野生型。
- 其他反复出现的突变包括TP53、Rb1和PIK3CA;部分病例中识别出非小细胞肺癌克隆再出现;转化后中枢神经系统转移常见。
关键数值与推荐
- 转化后铂类-依托泊苷和紫杉类均获得高反应率,但17例接受免疫治疗的患者中无一例出现反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Approximately 3% to 10% of EGFR (epidermal growth factor receptor) -mutant non-small cell lung cancers (NSCLCs) undergo transformation to small-cell lung cancer (SCLC), but their clinical course is poorly characterized. METHODS: We retrospectively identified patients with EGFR-mutant SCLC and other high-grade neuroendocrine carcinomas seen at our eight institutions. Demographics, disease features, and outcomes were analyzed. RESULTS: We included 67 patients-38 women and 29 men; EGFR mutations included exon 19 deletion (69%), L858R (25%), and other (6%). At the initial lung cancer diagnosis, 58 patients had NSCLC and nine had de novo SCLC or mixed histology. All but these nine patients received one or more EGFR tyrosine kinase inhibitor before SCLC transformation. Median time to transformation was 17.8 months (95% CI, 14.3 to 26.2 months). After transformation, both platinum-etoposide and taxanes yielded high response rates, but none of 17 patients who received immunotherapy experienced a response. Median overall survival since diagnosis was 31.5 months (95% CI, 24.8 to 41.3 months), whereas median survival since the time of SCLC transformation was 10.9 months (95% CI, 8.0 to 13.7 months). Fifty-nine patients had tissue genotyping at first evidence of SCLC. All maintained their founder EGFR mutation, and 15 of 19 with prior EGFR T790M positivity were T790 wild-type at transformation. Other recurrent mutations included TP53, Rb1, and PIK3CA. Re-emergence of NSCLC clones was identified in some cases. CNS metastases were frequent after transformation. CONCLUSION: There is a growing appreciation that EGFR-mutant NSCLCs can undergo SCLC transformation. We demonstrate that this occurs at an average of 17.8 months after diagnosis and cases are often characterized by Rb1, TP53, and PIK3CA mutations. Responses to platinum-etoposide and taxanes are frequent, but checkpoint inhibitors yielded no responses. Additional investigation is needed to better elucidate optimal strategies for this group.
引用
- Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2018. PMID: 30550363. doi:10.1200/JCO.18.01585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。